SIGLEC10 Human
SIGLEC10, PRO940, SLG2, SIGLEC-10, Sialic acid-binding Ig-like lectin 10 isoform 3, Siglec-like protein 2.
Greater than 85.0% as determined by SDS-PAGE.
Description
SIGLEC10 Human produced in Sf9 Insect cells is a single, glycosylated polypeptide chain containing 678 amino acids (17-455 a.a.) and having a molecular mass of 75.6kDa. SIGLEC10 is expressed with a 239 hIgG-His-tag at C-Terminus and purified by proprietary chromatographic techniques.
Product Specs
SIGLEC10, PRO940, SLG2, SIGLEC-10, Sialic acid-binding Ig-like lectin 10 isoform 3, Siglec-like protein 2.
MDGRFWIRVQ ESVMVPEGLC ISVPCSFSYP RQDWTGSTPA YGYWFKAVTE TTKGAPVATN
HQSREVEMST RGRFQLTGDP AKGNCSLVIR DAQMQDESQY FFRVERGSYV RYNFMNDGFF
LKVTALTQKP DVYIPETLEP GQPVTVICVF NWAFEECPPP SFSWTGAALS SQGTKPTTSH
FSVLSFTPRP QDHNTDLTCH VDFSRKGVSA QRTVRLRVAY APRDLVISIS RDNTPALEPQ
PQGNVPYLEA QKGQFLRLLC AADSQPPATL SWVLQNRVLS SSHPWGPRPL GLELPGVKAG
DSGRYTCRAE NRLGSQQRAL DLSVQYPPEN LRVMVSQANR TVLENLGNGT SLPVLEGQSL
CLVCVTHSSP PARLSWTQRG QVLSPSQPSD PGVLELPRVQ VEHEGEFTCH ARHPLGSQHV
SLSLSVHYKK GLISTAFSNL EPKSCDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR
TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN
GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR DELTKNQVSL TCLVKGFYPS
DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GKHHHHHH.
Product Science Overview
Siglec-10 is expressed on various immune cells, including dendritic cells, monocytes, B cells, natural killer (NK) cells, and T cells . It plays a crucial role in negatively regulating both innate and adaptive immune responses. This regulation is achieved through its interaction with CD24, which suppresses immune responses to danger-associated molecular patterns (DAMPs) by associating with the tyrosine phosphatase SHP-1, a negative regulator of nuclear factor-kappa B (NF-κB) .
Siglec-10 binds to sialic acids, which are commonly found on the surface of cells. This binding can inhibit the activation of immune cells, thereby preventing an overactive immune response. For instance, Siglec-10 has been shown to bind soluble CD52, leading to the impairment of phosphorylation of the T cell receptor-associated kinases Lck and Zap70, and subsequently, T cell activation . This mechanism is thought to be involved in maintaining T cell homeostasis and preventing autoimmune diseases such as type I diabetes .
Siglec-10’s role in immune regulation makes it a potential target for therapeutic interventions in various diseases. For example, its interaction with CD24 on tumor cells can inhibit the activation of immune cells, allowing tumors to evade the immune system . Blocking Siglec-10 has been proposed as a strategy to reactivate anti-tumor immunity . Additionally, Siglec-10 has been identified as the leukocyte ligand for vascular adhesion protein-1 (VAP-1), which plays a key role in leukocyte trafficking .
Human recombinant Siglec-10 is produced using recombinant DNA technology, which involves inserting the gene encoding Siglec-10 into a suitable expression system, such as bacteria or mammalian cells. This allows for the production of large quantities of the protein for research and therapeutic purposes. Recombinant Siglec-10 is used in various applications, including studying its function in immune regulation and developing potential therapeutic agents targeting Siglec-10 .
